Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSE Trial: Optimal Dose of Oral Corticosteroids for Asthma Exacerbations
NCT06833814Phase 4Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, double-blind trial of prednisone in asthma (3 arms). Primary endpoints: Enrollment rate at 9 months and Acceptability at 9 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
prednisone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06833814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833814.